



ISSN 2308-2097 (print)
ISSN 2518-7880 (online)

ДУ «Інститут гастроентерології НАМН України»

ФОРЛАКС

www.gastro.org.ua

ГАСТРОЕНТЕРОЛОГІЯ GASTROENTEROLOGY

ІНСТИТУТУ ГАСТРОЕНТЕРОЛОГІЇ 55 років

СМЕКТАЛІЯ®

Том 53,
№ 2,
2019

ЗАСЛАВСКИЙ
Издательский дом

www.mif-ua.com

альфлорекс™

B. infantis 35624™

Спеціально створений
для зменшення
всіх симптомів синдрому
 подразненого кишечника¹⁻⁴



1 капс./добу

ТОВ «БІОКОДЕКС УКРАЇНА»
пр. Степана Бандери, 28-А, літера Г, Київ, Україна, 04073.
Тел./факс: +38 (044) 237 77 84

BIOCODEX

ДУ «Інститут гастроентерології НАМН України»



Гастроентерологія

Gastroenterology

Gastroenterologia

Збірник наукових статей

Заснований у 1969 році

Періодичність виходу: 4 рази на рік

Том 53, № 2, 2019

Включений в наукометричні та спеціалізовані бази даних НБУ ім. В.І. Вернадського, «Україніка наукова», «Наукова періодика України», Ulrichsweb Global Serials Directory, CrossRef, WorldCat, Google Scholar, Science Index, «КіберЛенінка», ICMJE, SHERPA/RoMEO, OpenAIRE, BASE, ROAD, DOAJ, OAJI, Index Copernicus



mif-ua.com



journals.uran.ua



ГАСТРОЕНТЕРОЛОГІЯ GASTROENTEROLOGY

Збірник наукових статей

Том 53, № 2, 2019

DOI 10.22141/2308-2097.53.2.2019

ISSN 2308-2097 (print), ISSN 2518-7880 (online)

Передплатний індекс: 86164

УДК 616.35/34



Засновник

ДУ «Інститут гастроентерології НАМН України»

Адреса редакції:

Україна, 49074, м. Дніпро, пр. Слобожанський, 96

Тел.: +38 (056) 725-47-71, +38 (056) 227-00-84

www.gastro.org.ua

www.mif-ua.com

http://gastro.zaslavsky.com.ua

Електронні адреси для звертань:

З питань публікації статей

gastro_sbornik@i.ua

З питань передплати

info@mif-ua.com

Тел. +38 (044) 223-27-42

+38 (067) 325-10-26

З питань розміщення реклами

та інформації про лікарські засоби

reclama@mif-ua.com

office@zaslavsky.kiev.ua

selezneva@mif-ua.com

v_iliyna@ukr.net

Видання рекомендоване до друку та до поширення через мережу Інтернет вченою радою ДУ «Інститут гастроентерології НАМН України», протокол № 3 від 22.04.2019 р.

Зовнішні рецензенти:

проф. Абатуров О.Є., проф. Чухрієнко Н.Д.

Журнал внесено до переліку наукових фахових видань України, в яких можуть публікуватися результати дисертаційних робіт на здобуття наукових ступенів доктора і кандидата наук. Наказ МОН України від 21.12.2015 р. № 1328.

Українською, російською та англійською мовами

Свідчення про державну реєстрацію друкованого засобу масової інформації КВ № 20330-101301ПР. Видано Державною реєстраційною службою України 22.08.2013 р.

Формат: 60×84/8. Ум. друк. арк. 14,42.

Зам. 2019-gastro-72. Тираж 3000 прим.

Видавць Заславський О.Ю.

Адреса для листування: а/с 74, м. Київ, 04107

Свідчення суб'єкта видавничої справи

ДК № 2128 від 13.05.2005

Друк: ТОВ «Ландпрес»

Вул. Алчевських, 2, м. Харків, 61002

Головний редактор —

Степанов Ю.М.,

д.м.н., професор, директор

ДУ «Інститут гастроентерології НАМН України» (Дніпро)

Редакційна колегія:

Бабак О.Я., д.м.н., професор, завідувач кафедри внутрішньої медицини № 1 Харківського національного медичного університету (Харків)

Vincenzi Bruno, MD, PhD, Associate Professor in Medical Oncology, The Campus Bio-Medico University (Rome, Italy)

Губська О.Ю., д.м.н., професор, завідувач кафедри терапії, інфекційних хвороб та дерматовенерології Інституту післядипломної освіти НМУ імені О.О. Богомольця (Київ)

Діденко В.І., к.м.н., заступник директора з наукової роботи ДУ «Інститут гастроентерології НАМН України» (Дніпро)

Dumitrascu Dan L., MD, PhD AGAF, Iuliu Hațieganu University of Medicine and Pharmacy (Romania)

Мосійчук Л.М., д.м.н., зав. відділом захворювань шлунка, дванадцятипалої кишки, дієтології і лікувального харчування ДУ «Інститут гастроентерології НАМН України» (Дніпро)

Осьодло Г.В., д.м.н., професор, начальник кафедри військової терапії Української військово-медичної академії МО України (Київ)

Ратчик В.М., д.м.н., зав. відділом хірургії органів травлення ДУ «Інститут гастроентерології НАМН України» (Дніпро)

Свінцицький А.С., д.м.н., професор, академік АН ВШ України, завідувач кафедри внутрішніх хвороб стоматологічного факультету Національного медичного університету імені О.О. Богомольця (Київ)

Сірчак Є.С., д.м.н., професор, професор кафедри пропедевтики внутрішніх хвороб ВДНЗ «Ужгородський національний університет» (Ужгород)

Скрипник І.М., д.м.н., професор, проректор з науково-педагогічної роботи і післядипломної освіти Вищого державного навчального закладу України «Українська медична стоматологічна академія» (Полтава)

Фадєєнко Г.Д., д.м.н., професор, директор ДУ «Національний інститут терапії ім. академіка Л.Т. Малої НАМН України» (Харків)

Харченко Н.В., д.м.н., професор, чл.-кор. НАМН України, завідувач кафедри гастроентерології, дієтології і ендоскопії Національної медичної академії післядипломної освіти імені П.Л. Шупика (Київ)

Хухліна О.С., д.м.н., професор, завідувач кафедри внутрішньої медицини, клінічної фармакології та професійних хвороб ВДНЗ України «Буковинський державний медичний університет» (Чернівці)

Шевченко Б.Ф., д.м.н., професор, головний науковий співробітник відділу хірургії органів травлення ДУ «Інститут гастроентерології НАМН України» (Дніпро)

Відповідальний секретар:

Гравіровська Н.Г., к.м.н., пров. наук. співроб. (Дніпро)

Редакція не завжди поділяє думку автора публікації. Відповідальність за вірогідність фактів, власних імен та іншої інформації, використаної в публікації, несе автор. Передрук та інше відтворення в якій-небудь формі в цілому або частково статей, ілюстрацій або інших матеріалів дозволені тільки при попередній письмовій згоді редакції та з обов'язковим посиланням на джерело. Усі права захищені.

© ДУ «Інститут гастроентерології НАМН України», 2019

© Заславський О.Ю., 2019



ГАСТРОЕНТЕРОЛОГІЯ GASTROENTEROLOGY

Gastroenterologia

Gastroenterology

Collection of Scientific Articles

Volume 53, № 2, 2019

DOI 10.22141/2308-2097.53.2.2019

ISSN 2308-2097 (print), ISSN 2518-7880 (online)

Subscription index: 86164 (in Ukraine)

UDC 616.35/34



Founder

SI «Institute of Gastroenterology of NAMS of Ukraine»

Address of editorial office:

Slobozhanskii av., 96, Dnipro, Ukraine, 49074

Tel. +38(056) 725-47-71, +38(056) 227-00-84

www.gastro.org.ua

www.mif-ua.com

http://gastro.zaslavsky.com.ua

Correspondence e-mails:

Department of publishing article

gastro_sbornik@i.ua

Subscription department

info@mif-ua.com

Tel. +38 (044) 223-27-42

+38 (067) 325-10-26

Advertising and Drug

Promotion Department

reclama@mif-ua.com

office@zaslavsky.kiev.ua

selezneva@mif-ua.com

v_iliyna@ukr.net

Recommended for publication and circulation via the Internet on the resolution of Scientific Council of SI «Institute of Gastroenterology of NAMS of Ukraine», Protocol № 3 dated 22.04.2019.

External reviewers:

prof. Abaturov O.Ye., prof. Chukhriienko N.D.

The journal is entered into the list of specific scientific publications of Ukraine and can include doctoral and candidate theses. Order of Ministry of Health of Ukraine dated 21/12/2015 № 1328.

In Ukrainian, Russian and English

Registration certificate KB № 20330-101301P.

Issued by State Registration Service of Ukraine 22/08/2013

Folio 60×84/8. Printer's sheet 14,42.

Order 2019-gastro-72. Circulation 3000 copies.

Publisher Zaslavsky O.Yu.

Correspondence address: P.O.B. 74, Kyiv, Ukraine, 04107

Publishing entity certificate

ДК № 2128 dated 13/05/2005

Print: Landpress Ltd.

Alchevskyykh str., 2, Kharkiv, 61002

Editor-in-Chief

Yu.M. Stepanov,

MD, PhD, Professor, Director of SI "Institute of Gastroenterology of the NAMS of Ukraine" (Dnipro)

Editorial board:

Babak O.Ya., MD, PhD, Professor, Head of the Department of Internal Medicine 1 of Kharkiv National Medical University (Kharkiv)

Vincenzi Bruno, MD, PhD, Associate Professor in Medical Oncology, The Campus Bio-Medico University (Rome, Italy)

Gubskaya O.Yu., MD, PhD, Professor, Head of the Department of Therapy, Infectious Diseases and Dermatovenerology at the Institute of Postgraduate Education of Bogomolets NMU (Kyiv)

Didenko V.I., PhD, Deputy Research Director of SI "Institute of Gastroenterology of the NAMS of Ukraine" (Dnipro)

Dumitrascu Dan L., MD, PhD AGAF, Iuliu Hatieganu University of Medicine and Pharmacy (Romania)

Mosiichuk I.M., MD, PhD, Head of the Department of Gastrointestinal Diseases, Dietology and Clinical Nutrition of SI "Institute of Gastroenterology of the NAMS of Ukraine" (Dnipro)

Osiodlo H.V., MD, PhD, Professor, Head of the Department of Military Therapy of Ukrainian Military Medical Academy of the MoD of Ukraine (Kyiv)

Ratchyk V.M., MD, PhD, Head of the Department of Digestive Surgery of SI "Institute of Gastroenterology of the NAMS of Ukraine" (Dnipro)

Svitsitskiy A.S., MD, PhD, Professor, Academician of the AS of HS of Ukraine, Head of the Department of Internal Medicine of Stomatological Faculty of Bogomolets National Medical University (Kyiv)

Sirchak Ye.S., MD, PhD, Professor at the Department of Propedeutics of Internal Disease of HSEI "Uzhhorod National University" (Uzhhorod)

Skrypyk I.M., MD, PhD, Professor, Vice Rector for Academic Work and Postgraduate Education of Higher State Educational Institution of Ukraine "Ukrainian Medical Stomatological Academy" (Poltava)

Fadieienko H.D., MD, PhD, Professor, Director of SI "Mala National Institute of Therapy of the NAMS of Ukraine" (Kharkiv)

Kharchenko N.V., MD, PhD, Professor, Correspondence Member of the NAMS of Ukraine, Head of the Department of Gastroenterology, Dietology and Endoscopy of Shupyk National Medical Academy of Postgraduate Education (Kyiv)

Khukhlina O.S., MD, PhD, Professor, Head of the Department of Internal Medicine, Clinical Pharmacology and Occupational Diseases of HSEI of Ukraine "Bukovinian State Medical University" (Chernivtsi)

Shevchenko B.F., MD, PhD, Professor, Chief Researcher at the Department of Digestive Surgery of SI "Institute of Gastroenterology of the NAMS of Ukraine" (Dnipro)

Executive secretary:

Gravirovska N.H., Candidate of Medical Sciences, Leading Researcher (Dnipro)

The editorial board not always shares the author's opinion. The author is responsible for the significance of the facts, proper names and other information used in the paper. No part of this publication, pictures or other materials may be reproduced or transmitted in any form or by any means without permission in writing form with reference to the original. All rights reserved.

© SI «Institute of Gastroenterology of NAMS of Ukraine», 2019

© Zaslavsky O.Yu., 2019

Зміст

Contents

Оригінальні дослідження

Original Researches

Патологія верхніх відділів
травного каналуPathology of Upper
Gastrointestinal Tract

- Кушніренко І.В.*
Фактори ризику розвитку кандидозу
слизової оболонки верхнього відділу
шлунково-кишкового тракту.
Проблема антибіотикотерапії 9
- Степанов Ю.М., Саленко А.В.*
Кількісний аналіз швидкості
антисекреторного ефекту
комбінованого інгібітору
протонної помпи Езолонг 19

- I.V. Kushnirenko*
Risk factors for developing
mucosal candidiasis
of the upper gastrointestinal tract.
The problem of antibiotic therapy 9
- Yu.M. Stepanov, A.V. Salenko*
Quantitative analysis of the rate
of the antisecretory effect
of combined proton
pump inhibitor Ezolong 19

Патологія печінки
і жовчовивідної системиPathology of Liver
and Biliary Excretion System

- Матковська Н.Р., Вірстюк Н.Г., Балан У.В.*
Стан ендогенної інтоксикації
та імунізопальної реакції у хворих
на алкогольний цироз печінки
в поєднанні з неалкогольною
жировою хворобою печінки 24
- Сірчак Є.С., Грига В.І.,
Курчак Н.Ю., Куценко А.Ю.*
Зміни судин головного мозку
в пацієнтів із неалкогольною
жировою хворобою печінки
й порушенням вуглеводного обміну 33
- Степанов Ю.М.*
Результати обсерваційного перехресного
дослідження PRELID 2 (2015–2016).
Частина 2. Фактори ризику
неалкогольної жирової хвороби печінки
й методи лікування хвороби в пацієнтів,
які звертаються до терапевтів
і гастроентерологів в Україні 41
- Діденко В.І., Кленіна І.А.,
Татарчук О.М., Петішко О.П.*
Зв'язок імунологічних
та біохімічних показників у хворих
на хронічні дифузні захворювання печінки
залежно від етіологічних факторів
розвитку стеатозу і фіброзу печінки 50
- Маслова Г.С., Скрипник І.М.*
Оцінка факторів ризику розвитку
уражень печінки у хворих
на хронічну лімфоцитарну лейкомію
в динаміці хіміотерапії 58

- N.R. Matkovska, N.H. Virsiuk, U.V. Balan*
State of endogenous intoxication
and immune-inflammatory response
in patients with alcoholic liver
cirrhosis associated with non-alcoholic
fatty liver disease 24
- Ye.S. Sirchak, V.I. Griga,
N.Yu. Kurchak, A.Yu. Kutsenko*
Changes in the brain vessels
in patients with non-alcoholic
fatty liver disease and carbohydrate
metabolism disorder 33
- Yu.M. Stepanov*
Results of the observational
cross-over PRELID 2 study (2015–2016).
Part 2. Risk factors of non-alcoholic
fatty liver disease and treatment
options in patients seeking general
practitioners' and gastroenterologists'
help in Ukraine 41
- V.I. Didenko, I.A. Klenina,
O.M. Tatarchuk, O.P. Petishko*
Correlation of immunological
and biochemical indicators in patients
with chronic diffuse liver diseases
depending on the etiological factors
of steatosis and liver fibrosis 50
- G.S. Maslova, I.M. Skrypnyk*
Evaluating the risk factors for liver
injury in patients with chronic
lymphocytic leukemia
in the dynamics of chemotherapy 58

Патологія кишечника

Bowel Pathology

- Степанов Ю.М., Будзак І.Я., Гайдар Ю.А.*
Визначення міжклітинних контактів у хворих
із синдромом подразненого кишечника 63

- Yu.M. Stepanov, I.Ya. Budzak, Yu.A. Gaidar*
Determination of intercellular contacts
in patients with irritable bowel syndrome 63

Огляди та лекції

- Колеснікова О.В.
Погляд на фіброз печінки
у світлі розуміння сучасних
механізмів його розвитку 67
- Губська О.Ю., Кузьміна А.А.,
Гуцул В.М., Лавренчук І.О.
Кишковий мікробіом
й остеоартрит 78
- Ониськова О.В., Ющенко Л.О.,
Тихолаз В.О., Олійник В.С.,
Гордійчук О.О., Маланіна Т.В.
Основні підходи до профілактики
вірусного гепатиту А 92

Reviews and Lectures

- O.V. Kolesnikova
A take on liver fibrosis in the light
of understanding the modern
mechanisms of its development 67
- O.Yu. Gubska, A.A. Kuzminets,
V.M. Hutsul, I.O. Lavrenchuk
Intestinal microbiome
and osteoarthritis 78
- O.V. Oniskova, L.O. Yushchenko,
V.O. Tikholaz, V.S. Oleynik,
O.O. Gordiychuk, T.V. Malanina
The main approaches to the prevention
of viral hepatitis A 92

Новини фармкомпаній

- Чистик Т.В.
Гепажелс®: современные возможности
комплексной гепатопротекции
при хронических
заболеваниях печени 85

News of Pharmaceutical Companies

- T.V. Chistyuk
Hepahealth®: current options
of comprehensive
hepatoprotection
in chronic liver diseases 85

Матеріали конференції

- Чистик Т.В.
Неалкогольная жировая
болезнь печени:
патогенетические акценты
и подходы к терапии 97

Proceedings of the Conference

- T.V. Chistyuk
Неалкогольная жировая
болезнь печени:
патогенетические акценты
и подходы к терапии 97

Історія медицини

- Чабан М.П., Шевцова З.І.,
Гапонов В.В.
Тридцять років на земській службі:
штрихи до портрету
Надії Потапівни Кирпотенко —
однієї з перших жінок-лікарів
на Катеринославщині 106

History of Medicine

- M.P. Chaban, Z.I. Shevtsova,
V.V. Gaponov
Thirty years at the zemstvo work:
touches to the portrait
of Nadiia Potapivna Kyrpotenko,
one of the first female doctors
in the Katerynoslav area 106

Пам'яті вченого

- Ягмур С.С.
Светлой памяти профессора
Юлиана Исааковича Рафеса
(05.02.1924 — 23.02.2019).
Воспоминания о шефе 116

In Memoriam of the Scientist

- S.S. Yahmur
In loving memory of professor
Yulian Isaakovych Rafes
(05.02.1924 — 23.02.2019).
Memories of the chef 116

- Вимоги до оформлення статей** 120
Медицинская книга 122

- Requirements for the articles** 120
Medical book 122



UDC 616.36-003.826:616.133.33:612.015.32.39

DOI: 10.22141/2308-2097.53.2.2019.168983

Ye.S. Sirchak, V.I. Griga, N.Yu. Kurchak, A.Yu. Kutsenko
Uzhhorod National University, Uzhhorod, Ukraine

Changes in the brain vessels in patients with non-alcoholic fatty liver disease and carbohydrate metabolism disorder

Abstract. Background. The studies of brain vessels in patients with non-alcoholic fatty liver disease (NAFLD) can reveal new aspects of early detection of cerebral hemodynamic disorders, and will also allow the identification of a high-risk patients group. The purpose was to investigate the peculiarities of changes in the brain vessels in patients with NAFLD in combination with insulin resistance (IR) or type 2 diabetes mellitus (T2DM). **Materials and methods.** The study involved 74 patients with NAFLD (34 patients with non-alcoholic fatty hepatitis (NAFH) and 40 patients with non-alcoholic steatohepatitis (NASH)). The comparison group included 38 patients (16 patients with IR and 22 patients with T2DM). The condition of the blood flow in the brain was studied using ultrasound duplex scan of the extracranial portion of the common carotid artery (eCCA), the external carotid artery (eCA), the extracranial portion of the internal carotid artery, middle cerebral artery, the vertebral artery (VA), ophthalmic artery. The peak systolic velocity (PSV) and the time-average maximum (TAMX) of blood flow velocity in the studied vessels was determined. **Results.** The asymmetric damage to the vessels of the brain with more severe left ventricular dysfunction with NAFH is conspicuous; it is more pronounced in patients with the NASH stage, especially in combination with IR. Hemodynamically, the most significant changes were found in eCCA, namely, the decrease in PSV was found to be 38.1 ± 2.3 cm/s on the right, and 36.6 ± 3.4 cm/s on the left, TAMX reduction 20.4 ± 2.1 cm/s on the right, and 16.7 ± 1.8 cm/s on the left. **Conclusions.** The patients with NAFLD, as well as IR and T2DM had a decrease in the speed of blood flow in extracranial vessels of the brain, mainly in the eCCA, eCA and VA (segment 3). The most pronounced blood flow deficiency has been observed in patients with NASH in combination with IR, mainly on the left, especially in eCCA.

Keywords: non-alcoholic fatty liver disease; insulin resistance; type 2 diabetes mellitus; brain vessels

Introduction

Non-alcoholic fatty liver disease (NAFLD) is a clinical diagnosis that includes the presence of 5 % or more hepatic cells with fat accumulation as determined by liver imaging or biopsy in the absence of secondary causes of hepatic steatosis. NAFLD spans the spectrum of simple steatosis or non-alcoholic fatty liver to non-alcoholic steatohepatitis (NASH) which is defined histologically as hepatic steatosis, hepatic inflammation, and hepatocellular ballooning with or without fibrosis [1].

NAFLD is prevalent worldwide and is the most common chronic liver disease in Western countries. Its increasing prevalence is associated with major risk factors such as

obesity, dyslipidemia, type 2 diabetes mellitus (T2DM), and the metabolic syndrome [2].

NAFLD is a systemic disorder of energy, glucose, and lipid homeostasis with hepatic manifestations [3]. Metabolic disorders, such as lipid accumulation, insulin resistance (IR), and inflammation, have been implicated in the pathogenesis of NAFLD, but the underlying mechanisms, including those that drive disease progression, are not fully understood [4]. Therefore, the non-alcoholic fatty liver disease covers a range of diseases closely related to metabolic risk factors. As of today, the commonality of pathogenic mechanisms for NAFLD and metabolic syndrome has been proven, and their association with type 2 diabetes

© «Гастроентерологія» / «Гастроэнтерология» / «Gastroenterology» («Gastroenterologia»), 2019

© Видавець Заславський О.Ю. / Издатель Заславский А.Ю. / Publisher Zaslavsky O.Yu., 2019

Для кореспонденції: Сірчак Єлизавета Степанівна, доктор медичних наук, професор кафедри пропедевтики внутрішніх хвороб, медичний факультет, Ужгородський національний університет, пл. Народна, 3, м. Ужгород, 88000, Україна; e-mail: sirchakliza777@gmail.com; контактний тел.: +38 (050) 976-17-94.

For correspondence: Ye. Sirchak, MD, PhD, Professor at the Department of Propeaedeutics of Internal Diseases, Medical Faculty, Uzhhorod National University, Narodna sq., 3, Uzhhorod, 88000, Ukraine; e-mail: sirchakliza777@gmail.com; phone: +38 (050) 976-17-94.

mellitus, cardiovascular diseases and severe forms of liver disease, including cirrhosis and hepatocellular carcinoma, is evident [5].

It is believed that IR plays a central role in the development of NAFLD [6]. Patients with insulin resistance, as seen in obesity, metabolic syndrome, hypertension, and/or type 2 diabetes mellitus frequently exhibit endothelial dysfunction and are prone to develop arterial atherosclerosis, hypertension and metabolic disorders such as dysglycemia and elevated plasma free fatty acid levels. As a result of IR in patients with metabolic syndrome, type 2 diabetes, NAFLD, etc., endothelial dysfunction is formed, as well as vascular insulin resistance, combined with metabolic insulin resistance, that contribute to the development of hypertension and cardiovascular complications [7]. The associated physiological mechanisms are not fully appreciated yet, however, it seems that augmented oxidative stress, a physiological imbalance is a possible mechanism involved in various vascular beds with insulin resistance and hyperglycemia [8].

A growing body of literature now recognizes that deterioration in vascular function over time is a major contributor to the process of cognitive aging. Liver disease, particularly NAFLD, may be involved in the process of cognitive aging through several potential mechanisms. First, persons with NAFLD have a high prevalence of individual vascular risk factors (e.g., hypertension) that contribute to the progression of cognitive aging. Additional risk factors that may accelerate vascular aging include microvascular endothelial dysfunction in concert with high levels of liver-derived gamma-glutamyltransferase (GGT) and insulin-like growth factor-1. Second, the concurrent presence of chronic systemic inflammation and the metabolic syndrome, which are highly prevalent in NAFLD, have been shown to contribute to cognitive impairment. Finally, obesity, in particular visceral adiposity, is related to neurodegenerative, vascular, and metabolic processes that affect brain structures underlying cognitive function [9].

Therefore, the studies of brain vessels in patients with NAFLD can reveal new aspects of early detection of cerebral hemodynamic disorders, and will also allow the identification of a high-risk patients group who will need to undergo a correction of existing disorders in order to prevent cardiovascular catastrophe, especially when combined with NAFLD with IR, T2DM and obesity.

The purpose of the study was to investigate the peculiarities of changes in the brain vessels in patients with NAFLD in combination with IR or T2DM.

Materials and methods

At the clinical site of the Department of Propaedeutics of Internal Diseases of the Medical Faculty of SHEI "Uzhhorod National University" (Gastroenterology and Endocrinology Department in Novak Transcarpathia Region Clinical Hospital) during 2016–2019, 74 patients with NAFLD were examined. The average age was (47.8 ± 7.9) years. They formed the basic group of the examined patients (Group 1). Patients in Group 1 were divided into subgroups, namely:

— subgroup 1.1 included 34 patients with non-alcoholic fatty hepatosis (NAFH) (20 males (58.8 %) and 14 females (41.2 %), the average age was (47.7 ± 6.8) years);

— subgroup 1.2 included 40 patients with non-alcoholic steatohepatitis (24 males (60.0 %) and 16 females (40.0 %), the average age was (48.9 ± 6.8) years).

In order to achieve the aim of the research, the patients in the basic group (Group 1) were further divided into subgroups depending on the presence of type 2 diabetes (moderate to severe) or IR (Fig. 1).

The comparison group (Group 2) included 38 patients examined without laboratory-instrumental manifestations of liver damage, which in turn were divided into 2 subgroups, namely:

— subgroup 2.1 included 16 patients with IR (10 males (62.5 %) and 6 females (37.5 %), the average age was (42.4 ± 6.9) years);

— subgroup 2.2 included 22 patients with moderate to severe T2DM (13 males (59.1 %) and 9 females (40.9 %), the average age was (46.6 ± 4.1) years).

The control group included 20 apparently healthy persons (12 males (60.0 %) and 8 females (40.0 %)), the average age was (47.6 ± 5.8) years.

All studies were performed with patients' consent (written consent for performing appropriate diagnostic and therapeutic measures was received from all of the patients), and the methodology of their implementation met the World Medical Association Declaration of Helsinki (1975) and its revised version of 1983, and European Convention on Human Rights, as well as biomedicine and legislation of Ukraine.

All the examined patients were subject to general clinical, anthropometric, instrumental, and laboratory tests. The diagnosis was verified by complaints and history taking. In anthropometric study, height, weight, and waist circumferences were determined, and body mass index (BMI) was calculated. According to WHO recommendations, patients were divided based on BMI, where BMI of 16.0 and less corresponded to an expressed deficiency of body mass; 16.0–17.9 — insufficient body mass; 18.0–24.9 — normal body mass; 25.0–29.9 — excess weight; 30.0–34.9 — class I obesity; 35.0–39.9 — class II obesity; 40.0 and above — class III obesity (morbid obesity) [10].

Ultrasound examination of the abdominal cavity was performed in all patients according to generally accepted method. Standard and biochemical blood serum tests have been performed to determine the functional state of the liver, lipid metabolism indexes and carbohydrate metabolism (glucose, insulin, glycosylated hemoglobin (HbA1c, %) indexes).




Figure 1 — Distribution of patients with NAFLD depending on the presence of IR or T2DM

NA
the U
Minist
No. 82
tions f
Th
surrog
tors:
1.
of the
diabet
album
indica
<
(F0–F
≤
>
(F3–F
2.
the ag
and pl
—
presen
—
presen
3.
(U/L)
toglob
count.
Ins
(home
tance)
mally
H
>
Di
lished
as taki
col (th
Decer
was ev
UL
on Al
Medic
Notes
differ
Tom 53

NAFLD diagnosis was established in accordance with the Unified Clinical Protocol criteria (the Order of the Ministry of Health of Ukraine dated November 6, 2014, No. 826) and EASL-EASD-EASO Clinical Recommendations for Diagnosis and Treatment of NAFLD [11].

The degree of liver damage has been calculated using surrogate markers of fibrosis with the help of online calculators:

1. NAFLD fibrosis score: taking into account the age of the patients (years), BMI (kg/m²), glucose tolerance or diabetes mellitus, alanine aminotransferase (ALT, U/L), albumin (g/L), and the number of platelets (×10⁹/L). The indicator corresponds:

< -1.455: predictor of absence of significant fibrosis (F0–F2 fibrosis);

≤ -1.455 to ≤ 0.675: undetermined score;

> 0.675: predictor of presence of significant fibrosis (F3–F4 fibrosis).

2. Fibrosis 4 calculator: this formula takes into account the age of a patient (years), level of ALT (U/L), AST (U/L) and platelet count (×10⁹/L). Hence:

– an index lower than 1.45 – the probability of fibrosis presence is low (around 90 %);

– an index larger than 3.25 – the probability of fibrosis presence is high (around 90 %).

3. Fibrotest: here, the age (years), gender, GGT level (U/L), total bilirubin (μmol/L), apolipoprotein (g/L), haptoglobin (g/L), α₂-macroglobulin (g/L) are taken into account.

Insulin resistance was determined using the HOMA-IR (homeostasis model assessment method for insulin resistance), which was calculated according to a formula (normally HOMA-IR < 2.5):

$$\text{HOMA} = \text{fasting blood serum insulin } (\mu\text{U/mL}) \times \text{fasting blood plasma glucose (mmol/L)} / 22.5.$$

Diagnosis of type 2 diabetes mellitus has been established according to IDF recommendations (2005), as well as taking into account the criteria of unified clinical protocol (the Order of the Ministry of Health of Ukraine dated December 21, 2012, No. 1118) [12]. The severity of T2DM was evaluated by HbA_{1c} index (norm being up to 6.0 %).

Ultrasound evaluation of the head vessels was performed on Aloka ProSound 3500 SX (SSD-3500) (Hitachi Aloka Medical, China) apparatus using Aloka UST-5524-7.5 sen-

sor. The condition of the blood flow in the brain was studied using ultrasound duplex scan of the extracranial portion of the common carotid artery (eCCA), the external carotid artery (eCA), the extracranial portion of the internal carotid artery (eICA), middle cerebral artery (MCA), the vertebral artery (VA), ophthalmic artery (OA). The peak systolic velocity (PSV) and the time-average maximum (TAMX) of blood flow velocity in the studied vessels was determined. For the differential diagnosis of the atherosclerotic changes in brain vessels in the examined patients, eCCA posterior wall intima-media complex thickness was measured, since this is a marker of carotid atherosclerosis. The normal thickness of the intima-media complex for all patients is less than 1.0 mm. If the thickness index of intima-media complex of CCA posterior wall in the examined patients exceeded 1.0 mm, the patients were excluded from the study, and the results were considered as manifestations of atherosclerotic lesions of the brain vessels.

The criteria for exclusion of patients from the study were also: type 1 diabetes, type 2 diabetes (moderate to severe degrees, with severe manifestations of diabetic angioneuropathy), chronic hepatitis, alcoholic, viral (hepatitis B, C, D) etiologies, autoimmune hepatitis.

The scientific research was carried out within the scientific research work framework No. 851 "Mechanisms of the formation of complications in liver diseases and pancreas, methods of their treatment and prevention" (state registration number: 0115U001103), as well as the general department topic of the Department of Propaedeutics of Internal Diseases.

The analysis and processing of the examination results were carried out using the computer program Statistics for Windows 10.0 (StatSoft Inc., USA) using parametric and non-parametric methods of evaluating the results obtained.

Results

The anthropometric study found that the prevailing majority of the examined patients of both groups had overweight or obesity of varying classification (class I–II) (Table 1).

It is worth noting that among the patients with NAFH (Subgroup 1.1) and T2DM (Subgroup 2.2) people with class I obesity prevailed (*p* < 0.05), while among the patients with NASH (Subgroup 1.2) and IR (Subgroup 2.1) people with overweight were determined significantly more often. At the

Table 1 — Distribution of the patients according to BMI

BMI	Group 1 (n = 74)		Group 2 (n = 38)	
	Subgroup 1.1 (n = 34)	Subgroup 1.2 (n = 40)	Subgroup 2.1 (n = 16)	Subgroup 2.2 (n = 22)
Normal weight, % 18.0–24.9 kg/m ²	8.8 22.3 ± 2.7	12.5 20.3 ± 4.6*	18.8 23.7 ± 3.1	13.6 22.1 ± 4.4
Overweight, % 25.0–29.9 kg/m ²	29.4 27.0 ± 4.1	45.0* 26.6 ± 3.3	50.0# 28.4 ± 3.5#	27.3 26.5 ± 2.7
Class I obesity, % 30.0–34.9 kg/m ²	50.0* 33.7 ± 2.5*	25.0 31.6 ± 1.9	25.0 34.1 ± 3.3#	40.9# 31.7 ± 2.8
Class II obesity, % 35.0–39.9 kg/m ²	11.8 37.9 ± 4.1	17.5 37.1 ± 3.5	6.2 38.9 ± 5.3	18.2 36.1 ± 3.2

Notes: the difference between the indexes of Group 1 within the subgroups is significant: * — *p* < 0.05; the difference between the indexes of Group 2 is significant: # — *p* < 0.05.

same time, among the patients from Group 1, higher BMI indexes within the limits of corresponding malnutrition degree were determined in those with NAFH (Subgroup 1.1), and among patients with carbohydrate metabolism disorder — among those examined for IR (Subgroup 2.1).

The study of the carbohydrate metabolism indexes confirmed the presence of IR in patients in Subgroup 2.1 and T2DM in patients in Subgroup 2.2. At the same time, an increase in insulin level in patients with T2DM (moderate to severe) is a compensatory mechanism of the body for insulin resistance, as indicated by the high index of HOMA-IR in patients in Subgroup 2.1.

While characterizing carbohydrate metabolism, namely IR, at NAFLD, differences were found in patients with NAFH and NASH, namely, more severe hyperinsulinemia in patients with NAFH ((44.7 ± 6.5) U/L), which is associated with a more severe IR. Fasting glycemic indices were also higher in NAFH patients: glucose level in patients in the Subgroup 1.1A was (7.95 ± 0.24) mmol/l, and HbA1c — (7.98 ± 0.36) %.

It should be noted that more severe disorders of carbohydrate metabolism were found when combined with type 2 diabetes or IR with NAFLD than without it. In this case, the maximum deviations from the parameters of the control group were established in patients in Subgroup 1.1A (NAFH in combination with IR) (Tables 2, 3).

The Tables 4, 5 demonstrate that all examined subgroups of both groups revealed changes in the velocity of blood flow in the vessels of the brain by the results of duplex scan.

The average blood flow velocity in both external and internal carotid arteries in patients with both T2DM (Subgroup 2.2) and IR (Subgroup 2.1) was determined. The maximum deviations from the norm were found in the blood flow rates according to eCCA, namely, the decrease of PSV to (50.2 ± 2.2) cm/s on the right and to (51.0 ± 3.6) cm/s to the left in patients in the Subgroup 2.1, and to (51.0 ± 1.8) cm/s on the right and up to (50.6 ± 2.4) cm/s to the left in the patients in the Subgroup 2.2. TAMX is also believed to be significantly lower in patients with type 2 diabetes. In the study of segments 3 and 4 of VA, a blood flow deficit on both sides in patients in Group 2 was also diagnosed. It should be noted that a significant difference in the studied parameters in patients with type 2 diabetes was not detected in Group 2 (Table 4).

Patients with NAFLD revealed significant deviations from the norm in blood flow rates in the study of major vessels of the brain (Table 5). At the same time, in patients with NAFH in both 1.1A and 1.1B Subgroups, the indicators did not significantly differ from those in patients with IR (Subgroup 2.1) or T2DM (Subgroup 2.2) without liver damage. Maximum changes in blood flow to extracranial vessels of the brain are found in patients with NASH (Subgroups 1.2). At the same time, the difference in these indicators, depending on the presence of IR (Subgroup 1.2A) or type 2 DM (Subgroup 1.2B) was not established.

The asymmetric damage to the vessels of the brain with more severe left ventricular dysfunction with NAFH is conspicuous; that is more pronounced in patients with the

Table 2 — Changes in carbohydrate metabolism in Group 2 patients (with T2DM and IR) and the control group

Index	Control group	Group 2 (n = 38)	
		Subgroup 2.1 (n = 16)	Subgroup 2.2 (n = 22)
Glucose (mmol/L)	4.51 ± 0.41	6.58 ± 0.33*	7.82 ± 0.26*
HbA1c (%)	4.38 ± 0.26	6.73 ± 0.28*	7.91 ± 0.15*
Insulin (U/L)	9.20 ± 1.14	36.21 ± 5.57**.#	19.77 ± 2.42*
C-peptide (ng/mL)	4.54 ± 0.97	16.21 ± 1.88**,+	11.73 ± 1.26**
HOMA-IR	1.71 ± 0.32	10.42 ± 2.61**+	6.23 ± 0.40**

Notes: the difference between the indices in patients of the Group 2 and the control group is significant: * — p < 0.05; ** — p < 0.01; the difference between the indices in patients of the Group 2 in the subgroups is significant: + — p < 0.05; # — p < 0.01.

Table 3 — Changes of carbohydrate metabolism parameters in patients in Group 1 (patients with NAFH and NASH) depending on presence of T2DM or IR

Indicator	Participants in Group 1 with NAFLD			
	Subgroup 1.1 (n = 34)		Subgroup 1.2 (n = 40)	
	Subgroup 1.1A (n = 16)	Subgroup 1.1B (n = 18)	Subgroup 1.2A (n = 20)	Subgroup 1.2B (n = 20)
Glucose (mmol/L)	6.95 ± 0.27*	7.95 ± 0.24*	6.75 ± 0.31*	7.87 ± 0.19*
HbA1c (%)	6.88 ± 0.36*	7.98 ± 0.36*	6.80 ± 0.36*	7.89 ± 0.23*
Insulin (U/L)	44.7 ± 6.5**,+	29.7 ± 3.3**	38.4 ± 4.1**,+	21.3 ± 1.7*
C-peptide (ng/mL)	21.77 ± 2.31**	14.56 ± 1.45**,+	17.41 ± 1.67**	12.33 ± 1.22**,+
HOMA-IR	12.81 ± 3.26**	10.41 ± 2.90**	11.32 ± 2.78**,+	7.44 ± 0.23**

Notes: the difference between the indicators in patients of Group 1 and control group is significant: * — p < 0.05; ** — p < 0.01; the difference between the indices in patients of Group 1 by subgroups is significant: + — p < 0.05; ** — p < 0.01.

NASH
1.2A).
found
decrea
right, a
to be (1
on the
on the
tion of
(18.4 ±
A c
relatio
brain v
Mo
the blo

Tab

eCCA

eCA

elCA

MCA

VA,
segm

VA,
segm

OA

Note:

NASH stage, especially in combination with IR (Subgroup 1.2A). Hemodynamically, the most significant changes were found in eCCA and in the 3rd segment of VA, namely, the decrease in PSV was found to be (38.1 ± 2.3) cm/s on the right, and (36.6 ± 3.4) cm/s on the left, TAMX reduction to be (20.4 ± 2.1) cm/s on the right, and (16.7 ± 1.8) cm/s on the left of eCCA; reduction of PSV to (40.1 ± 2.2) cm/s on the right, and up to (35.5 ± 1.7) cm/s on the left, reduction of TAMX to (18.4 ± 1.0) cm/s on the right, and up to (18.4 ± 1.0) cm/s to the left of the 3rd segment VA.

A detailed statistical analysis enabled to establish the relationship between the violation of the blood flow in the brain vessels and IR severity.

More often, the correlation between the violation of the blood flow in the vessels of the brain (in eCCA, eCA

and VA (segment 3)) and IR severity with the HOMA index was found only in patients with NASH in combination with IR (Subgroup 1.2A). In patients in Subgroup 1.1A, the dependence is established only on the parameters of blood flow on eCCA and VA, and in patients 2.1 — only on eCCA (Table 6). Consequently, IR plays a leading role in the formation of a blood flow deficit in the main vessels of the brain in patients with NAFLD.

Discussion

The obtained results indicate that NAFLD, IR, T2DM, and their combination are more likely to occur in persons with excessive body weight and obesity. The evaluation of carbohydrate metabolism indexes showed that IR is more pronounced in patients with NAFH stage than with

Table 4 — Parameters of ultrasound examination of extracranial brain blood vessels in patients with T2DM or with IR and in the control group, cm/s

Index			Participants		
Arterial segment			Control group (n = 20)	Comparison groups (Group 2, n = 38)	
				Subgroup 2.1 (IR, n = 16)	Subgroup 2.2 (type 2 DM, n = 22)
eCCA	PSV	right	73.4 ± 4.6	50.2 ± 2.2*	51.0 ± 1.8*
		left	71.7 ± 5.0	51.0 ± 3.6*	50.6 ± 2.4*
	TAMX	right	44.8 ± 3.2	38.2 ± 1.4	37.4 ± 2.2
		left	45.5 ± 3.7	37.9 ± 0.9	37.9 ± 1.8
eCA	PSV	right	61.5 ± 3.9	49.2 ± 1.7*	48.7 ± 0.9*
		left	62.9 ± 2.7	48.9 ± 1.9*	47.3 ± 2.3*
	TAMX	right	38.3 ± 2.2	31.1 ± 0.9	31.4 ± 1.6
		left	37.0 ± 3.1	30.9 ± 2.1	31.0 ± 1.5
elCA	PSV	right	53.6 ± 5.8	45.5 ± 1.7	44.9 ± 2.3*
		left	55.9 ± 5.4	45.7 ± 2.1	43.8 ± 3.7*
	TAMX	right	34.7 ± 2.0	28.7 ± 0.8	27.6 ± 1.2
		left	33.0 ± 2.6	29.0 ± 1.3	28.7 ± 1.7
MCA	PSV	right	96.4 ± 6.7	86.4 ± 3.2*	85.9 ± 2.1*
		left	91.5 ± 7.1	87.3 ± 5.5	86.9 ± 3.0
	TAMX	right	65.3 ± 2.6	60.1 ± 1.2	59.8 ± 2.0
		left	65.8 ± 3.3	60.5 ± 0.7	60.4 ± 0.9
VA, segment 3	PSV	right	46.6 ± 3.9	41.2 ± 1.1	40.9 ± 2.7
		left	46.0 ± 1.9	40.9 ± 1.6	41.3 ± 0.7
	TAMX	right	27.3 ± 1.6	20.8 ± 0.7	21.0 ± 0.5
		left	27.0 ± 1.9	21.1 ± 1.0	21.3 ± 1.2
VA, segment 4	PSV	right	57.9 ± 3.1	43.0 ± 1.8*	43.3 ± 2.3*
		left	56.8 ± 2.5	42.7 ± 2.0*	42.9 ± 1.8*
	TAMX	right	38.9 ± 3.0	28.7 ± 2.1*	27.7 ± 1.7*
		left	39.1 ± 2.6	28.0 ± 1.6*	28.2 ± 1.0*
OA	PSV	right	47.0 ± 3.1	42.4 ± 1.7	41.7 ± 2.6
		left	47.9 ± 2.6	43.4 ± 1.1	42.8 ± 1.9
	TAMX	right	24.7 ± 0.9	24.3 ± 0.5	24.4 ± 1.0
		left	25.8 ± 1.2	24.6 ± 1.4	25.0 ± 0.9

Note: the difference between the indices in patients of the Group 2 and the control group is significant: * — p < 0.05.

Table 5 — Parameters of ultrasound extracranial brain blood vessels examination of NAFLD patients, cm/s

Index			NAFLD patients in the basic Group 1			
Arterial segment			Subgroup 1.1 (patients with NAFH)		Subgroup 1.2 (patients with NASH)	
			Subgroup 1.1A NAFH and IR (n = 16)	Subgroup 1.1B NAFH and T2DM (n = 18)	Subgroup 1.2A NASH and IR (n = 20)	Subgroup 1.2B NASH and T2DM (n = 20)
eCCA	PSV	right	49.3 ± 2.7**	49.1 ± 1.7**	38.1 ± 2.3**.#	38.0 ± 1.7**.#
		left	48.8 ± 2.7*	48.5 ± 2.0*	36.6 ± 3.4**.#	36.0 ± 2.2**.#
	TAMX	right	37.5 ± 1.8	37.9 ± 1.5	20.4 ± 2.1**.#	19.4 ± 1.7**.#
		left	37.0 ± 1.1	37.0 ± 2.1	16.7 ± 1.8**.#	15.90 ± 1.84*.#
eCA	PSV	right	48.7 ± 1.2*	47.4 ± 1.2*	45.6 ± 2.1*	45.1 ± 2.0*
		left	47.2 ± 1.4*	46.8 ± 1.4*	44.2 ± 1.9*	43.9 ± 1.7*
	TAMX	right	30.9 ± 0.8	30.6 ± 1.3	23.5 ± 2.0*.#	23.7 ± 1.7*.#
		left	29.8 ± 1.7	30.0 ± 1.8	22.1 ± 0.9*.#	21.9 ± 1.0*.#
eICA	PSV	right	45.0 ± 1.1	44.4 ± 1.6*	42.1 ± 2.3*	42.2 ± 1.8*
		left	44.7 ± 2.0	43.0 ± 3.7*	41.6 ± 1.9*	41.1 ± 0.7*
	TAMX	right	28.0 ± 0.7	27.1 ± 1.8	25.4 ± 2.1*	25.6 ± 2.2*
		left	28.1 ± 1.7	27.3 ± 1.1	24.7 ± 2.0*	24.0 ± 1.7*
MCA	PSV	right	86.2 ± 3.0*	85.7 ± 3.1*	84.7 ± 2.6*	83.9 ± 2.8*
		left	84.2 ± 3.6	85.0 ± 2.7	83.7 ± 2.9*	83.0 ± 1.6*
	TAMX	right	59.7 ± 1.0	59.0 ± 2.6	54.7 ± 1.7*	55.7 ± 1.4*
		left	58.9 ± 0.7	58.8 ± 1.8	53.2 ± 1.7*	53.1 ± 1.2*
VA, segment 3	PSV	right	40.7 ± 2.3	39.7 ± 2.5	40.1 ± 2.2	40.6 ± 2.1
		left	40.0 ± 0.6	39.2 ± 1.4	35.5 ± 1.7*	35.0 ± 1.4*
	TAMX	right	20.1 ± 0.4	20.1 ± 0.7	18.4 ± 1.0*	17.1 ± 0.9*
		left	20.3 ± 0.8	19.5 ± 1.7*	15.3 ± 1.2*	15.0 ± 1.7*
VA, segment 4	PSV	right	42.6 ± 1.7*	42.7 ± 1.4*	41.1 ± 0.7*	40.8 ± 1.1*
		left	41.5 ± 1.5*	41.0 ± 0.9*	40.2 ± 0.7*	40.1 ± 1.1*
	TAMX	right	27.9 ± 1.6*	27.0 ± 2.0*	19.8 ± 1.1*	19.2 ± 0.3*
		left	27.4 ± 1.2*	26.3 ± 0.8*	19.0 ± 0.4*	18.9 ± 0.7*
OA	PSV	right	42.8 ± 2.5	41.4 ± 1.4	41.5 ± 2.0	41.7 ± 1.6
		left	41.9 ± 2.1	40.7 ± 1.3	39.2 ± 1.6*	38.9 ± 1.1*
	TAMX	right	24.1 ± 1.2	24.0 ± 1.0	23.1 ± 1.1	23.1 ± 2.1
		left	24.3 ± 0.9	24.1 ± 0.6	23.0 ± 0.7	23.9 ± 0.8

Notes: the difference between the indices in patients of the Group 1 and the control group is significant: * — $p < 0.05$, ** — $p < 0.05$; the difference between the indicators in patients of the Group 1 in the subgroups is significant: # — $p < 0.05$.

Table 6 — Correlation between parameters of blood flow in great brain blood vessels and IR based on HOMA-IR index

Parameters of examined vessels		HOMA-IR		
		Subgroup 1.1A (NAFH and IR)	Subgroup 1.2A (NASH and IR)	Subgroup 2.1 (IR)
eCCA	PSV	r = 0.47; p < 0.05	r = 0.92; p < 0.01	r = 0.76; p < 0.01
	TAMX	r = 0.50; p < 0.05	r = 0.88; p < 0.01	r = 0.64; p < 0.05
eCA	PSV	—	r = 0.74; p < 0.01	—
	TAMX	—	r = 0.69; p < 0.05	—
VA, segment 3	PSV	r = 0.56; p < 0.05	r = 0.57; p < 0.05	—
	TAMX	r = 0.62; p < 0.05	r = 0.49; p < 0.05	—

NAS
(11.3
in the
inclu
ders v
V
tus,
chang
volum
(B. F
mody
lead t
tive in
A
NAF
comp
tery,
sis an
study
a sub
asym
preva
sclero
with
assoc
sels [
mine
NAF
T
the v
with
fican
dyna
liver
result
of IR
of blo
NAF
prese
pron
is rev
C
the fe
bolio
lar ch
which
the li
prod
stanc
lar sy
F
gress
drate
of liv
impa
Cor
1
well a
flow

NASH (according to the HOMA index: 12.81 ± 3.26 and 11.32 ± 2.78), respectively). Thus, IR is the key mechanism in the progression of lesions of various organs and systems, including the vascular bed, in patients with metabolic disorders with NAFLD.

Various studies paid attention to psychological status, cognitive impairment, as well as their association with changes in the structure of the brain (with a decrease in the volume of white matter) and the severity of fibrosis at NAFH (B. Filipović et al., 2018) [13]. It is believed that cerebral hemodynamics due to disruptions in the microcirculation can lead to structural changes in the brain that underlie cognitive impairment (L.B. VanWagner et al., 2017) [9].

According to A. Rasool et al. (2017), all patients with NAFLD should be subjected to a study of the intima-media complex of the posterior wall of the common carotid artery, since NAFLD is associated with carotid atherosclerosis and, consequently, coronary atherosclerosis [14]. In the study of Y.J. Lee et al. (2018), NAFLD was associated with a subclinical form of cerebrovascular atherosclerosis in an asymptomatic general population of Korean men. Higher prevalence of subclinical form of cerebroid-cardiac atherosclerosis was observed in patients with NAFLD compared with controls without NAFLD. In addition, NAFLD was associated with a higher risk of atherosclerosis in large vessels [15]. Another study (L. Airaghi et al., 2018) also examined subclinical cerebrovascular lesions in patients with NAFLD, but without risk factors for atherosclerosis [16].

The results obtained by us testify to the impairment of the vascular pool of the brachiocephalic trunk in patients with NAFLD, type 2 diabetes and IR. There was no significant difference between the indicators of cerebral hemodynamics in patients with type 2 diabetes and IR (without liver damage). In fact, it does not differ from the data and results of patients with NAFLD (regardless of the presence of IR or DM). Our data indicate the maximum slowing of blood flow to the vessels of the brain in patients with NAFLD at the stage of steatohepatitis (regardless of the presence of IR or DM). In this case, asymmetry with more pronounced deceleration of velocity indicators to the left is revealed.

Consequently, insulin resistance plays a leading role in the formation of vascular tract defects in patients with metabolic disorders (liver steatosis, obesity, T2DM, etc.). Vascular changes are more pronounced in patients with NASH, which is probably due to a decrease in functional reserve of the liver, which in turn contributes to the reduction of the production/deactivation of vascular active biological substances, which together with the IR is the basis of the vascular system damage, including cerebral hemodynamics.

Further research is needed to better understand the progression of vascular lesions in NAFLD and in the carbohydrate metabolism, taking into account risk factors, severity of liver damage, IR and type 2 diabetes as well as cognitive impairment in these patients.

Conclusions

1. The patients with NAFLD (NAFH and NASH), as well as IR and T2DM had a decrease in the velocity of blood flow in extracranial vessels of the brain, mainly in the com-

mon carotid artery, external carotid artery and vertebral artery (segment 3).

2. There was no statistically significant difference between the indicators of cerebral hemodynamics in patients with IR, type 2 diabetes mellitus (mild course) and NAFH (regardless of type of IR or DM).

3. The most pronounced blood flow deficiency has been observed in patients with NASH in combination with IR, mainly on the left, especially in eCCA (PSV reduction to 38.1 ± 2.3 cm/s on the right and up to 36.6 ± 3.4 cm/s on the left, and also TAMX decrease to 20.4 ± 2.1 cm/s on the right and to 16.7 ± 1.8 cm/s on the left).

Conflicts of interests. Authors declare the absence of any conflicts of interests that might be construed to influence the results or interpretation of their manuscript.

Contribution of the authors

Sirchak Ye.S. — conception and design of the study; analysis of obtained data; **Griga V.I.** — collection and processing of data, text writing; **Kurchak N.Yu.** — collection of the material; **Kutsenko A.Yu.** — performance of ultrasound investigation of great brain vessels.

References

1. Carr R.M. Non-alcoholic fatty liver disease: Pathophysiology and management / R.M. Carr, A. Oranu, V. Khungar // *Gastroenterol. Clin. North Am.* — 2016. — № 45 (4). — P. 639-652.
2. Lim H.-W. Risk factors for the development of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, including genetics / H.-W. Lim, D.E. Bernstein // *Clinics in Liver Disease.* — 2018. — Vol. 22, Issue 1. — P. 39-57.
3. Pickett-Blakely O. Micronutrients in Nonalcoholic Fatty Liver Disease Pathogenesis / O. Pickett-Blakely, K. Young, R.M. Carr // *Cellular and Molecular Gastroenterology and Hepatology.* — 2018. — Vol. 6, Issue 4. — P. 451-462.
4. Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments / H. Kitade, G. Chen, Y. Ni, T. Ota // *Nutrients.* — 2017. — № 9 (4). — P. 387.
5. Неалкогольна жирова хвороба печінки: особливості метаболічних змін на різних етапах розвитку хвороби / Ю.М. Степанов, Н.В. Недзвецька, В.Б. Ягмур, І.А. Клеїна // *Гастроентерологія.* — 2018. — Т. 52, № 1. — С. 13-18.
6. Asrih M. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance / M. Asrih, F.R. Jornayvaz // *Journal of Endocrinology.* — 2013. — Vol. 218 (3). — P. 25-36.
7. Zheng C. Vascular Function, Insulin Action and Exercise: An Intricate Interplay / C. Zheng, L. Zhenqi // *Trends Endocrinol. Metab.* — 2015. — № 26 (6). — P. 297-304.
8. Hwang M.-H. Insulin resistance: vascular function and exercise / M.-H. Hwang, S. Lee // *Integr. Med. Res.* — 2016. — № 5. — P. 198-203.
9. Nonalcoholic Fatty Liver Disease and Measures of Early Brain Health in Middle Aged Adults: The CARDIA study / L.B. VanWagner, J.G. Terry, L.S. Chow et al. // *Obesity.* — 2017. — № 25 (3). — P. 642-651.
10. WHO: Global Database on Body Mass Index. Available at: http://apps.who.int/bmi/index.jsp?introPage=intro_3.html

11. *EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease / European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) // Journal of Hepatology. — 2016. — Vol. 64. — P. 1388-1402.*

12. Гульчій М.В. Цукровий діабет 2 типу / М.В. Гульчій, Л.Ф. Матюха, В.З. Нетяженко та ін. // Адаптована клінічна настанова, заснована на доказах. — Київ, 2012. — 343 с.

13. *Cognitive Changes and Brain Volume Reduction in Patients with Nonalcoholic Fatty Liver Disease / B. Filipović, O. Marković, V. Yuric, B. Filipović // Canadian Journal of Gastroenterology and Hepatology. — Vol. 2018. — Article ID 9638797.*

14. *Rasool A. Nonalcoholic fatty liver disease as an independent risk factor for carotid atherosclerosis / A. Rasool, W. Dar, M. Latief et al. // Brain Circulation. — 2017. — Vol. 3, Issue 1. — P. 35-40.*

15. *Lee J.E. Severity of nonalcoholic fatty liver disease is associated with subclinical cerebro-cardiovascular atherosclerosis risk in Korean men / J.E. Lee, Y.J. Lee, S.Y. Chung et al. // PloS One. — 2018. — № 13 (3). — e0193191.*

16. *Airaghi L. Subclinical cerebrovascular disease in NAFLD without overt risk factors for atherosclerosis / L. Airaghi, M. Rango, D. Maira et al. // Atherosclerosis. — 2018. — Vol. 268. — P. 27-31.*

Received 28.03.2019 ■

Сірчак Е.С., Грига В.І., Курчак Н.Ю., Куценко А.Ю.
ДВНЗ «Ужгородський національний університет», м. Ужгород, Україна

Зміни судин головного мозку в пацієнтів із неалкогольною жировою хворобою печінки й порушенням вуглеводного обміну

Резюме. *Актуальність.* Дослідження судин головного мозку в пацієнтів із неалкогольною жировою хворобою печінки (НАЖХП) може розкрити нові аспекти щодо раннього виявлення порушень церебральної гемодинаміки, а також дозволить визначити групу хворих високого ризику. *Мета дослідження:* дослідити особливості зміни судин головного мозку в пацієнтів із НАЖХП у поєднанні з інсулінорезистентністю (ІР) чи цукровим діабетом (ЦД) 2 типу. *Матеріали та методи.* Обстежено 74 пацієнтів із НАЖХП (34 хворі з неалкогольним жировим гепатозом (НАЖГ) та 40 хворих з неалкогольним стеатогепатитом (НАСГ)). Група порівняння включала 38 пацієнтів (16 хворих з ІР та 22 пацієнтів з ЦД 2 типу). Стан кровотоку в судинах головного мозку вивчали за допомогою ультразвукового дуплексного сканування екстракраніального відділу загальної сонної артерії (ЗагСА), зовнішньої сонної артерії (ЗовСА), екстракраніального відділу внутрішньої сонної артерії, середньої мозкової артерії, вертебральної артерії (ВА), очної артерії. Визначали пікову систолічну швидкість

(ПСС) та середню за часом максимальну швидкість кровотоку (ТАМХ) в досліджуваних судинах. *Результати.* Звертає на себе увагу асиметричне ураження судин головного мозку з більш вираженим дефіцитом кровотоку зліва при НАЖХП, що більш виражене у хворих зі стадією НАСГ, особливо у поєднанні з ІР. Гемодинамічно найбільш значущі зміни встановлено в ЗагСА, а саме виявлене зниження ПСС до $(38,1 \pm 2,3)$ см/с справа та до $(36,6 \pm 3,4)$ см/с зліва, зниження ТАМХ — до $(20,4 \pm 2,1)$ см/с справа та до $(16,7 \pm 1,8)$ см/с зліва. *Висновки.* У хворих із НАЖХП, а також із ІР та ЦД 2 типу виявлене зниження швидкісних показників кровотоку по екстракраніальних судинах головного мозку, переважно по ЗагСА, ЗовСА та ВА (сегмент 3). Найбільш виражений дефіцит кровотоку встановлений у хворих на НАСГ у поєднанні з ІР, переважно зліва, особливо по ЗагСА.

Ключові слова: неалкогольна жирова хвороба печінки; інсулінорезистентність; цукровий діабет 2 типу; судини головного мозку

Сирчак Е.С., Грига В.И., Курчак Н.Ю., Куценко А.Ю.
ГВУЗ «Ужгородский национальный университет», г. Ужгород, Украина

Изменения сосудов головного мозга у пациентов с неалкогольной жировой болезнью печени и нарушением углеводного обмена

Резюме. *Актуальность.* Исследование сосудов головного мозга у пациентов с неалкогольной жировой болезнью печени (НАЖБП) может раскрыть новые аспекты раннего выявления нарушений церебральной гемодинамики, а также обнаружить группу больных высокого риска. *Цель исследования:* изучить особенности изменений в сосудах головного мозга у пациентов с НАЖБП в сочетании с инсулинорезистентностью (ИР) или сахарным диабетом (СД) 2 типа. *Материалы и методы.* Обследовано 74 пациента с НАЖБП (34 больных с неалкогольным жировым гепатозом (НАЖГ) и 40 больных с неалкогольным стеатогепатитом (НАСГ)). Группа сравнения включала 38 пациентов (16 больных с ИР и 22 пациента с СД 2 типа). Состояние кровотока в сосудах головного мозга изучали с помощью ультразвукового дуплексного сканирования экстракраниального отдела общей сонной артерии (ОСА), наружной сонной артерии (НСА), экстракраниального отдела внутренней сонной артерии, средней мозговой артерии, вертебральной артерии (ВА), глазной артерии. Определяли пиковую систолическую

скорость (ПСС) и среднюю по времени максимальную скорость кровотока (ТАМХ) в исследуемых сосудах. *Результаты.* Обращает на себя внимание асимметричное поражение сосудов головного мозга с более выраженным дефицитом кровотока слева при НАЖБП, что более выражено у больных со стадией НАСГ, особенно в сочетании с ИР. Гемодинамически наиболее значимые изменения установлены в ОСА, а именно выявлено снижение ПСС до $(38,1 \pm 2,3)$ см/с справа и до $(36,6 \pm 3,4)$ см/с слева, снижение ТАМХ — до $(20,4 \pm 2,1)$ см/с справа и до $(16,7 \pm 1,8)$ см/с слева. *Выводы.* У пациентов с НАЖБП, ИР и СД 2 типа выявлено снижение скоростных показателей кровотока по экстракраниальным сосудам головного мозга, преимущественно по ОСА, НСА и ВА (сегмент 3). Наиболее выраженный дефицит кровотока установлен у больных НАСГ в сочетании с ИР, преимущественно слева, особенно по ОСА.

Ключевые слова: неалкогольная жировая болезнь печени; инсулинорезистентность; сахарный диабет 2 типа; сосуды головного мозга